Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma

Abstract Background: Recent studies have highlighted that TACE in conjunction with Lenvatinib (TACE-L) offers a promising adjunct therapy for advanced HCC patients, outperforming TACE plus Sorafenib (TACE-S). However, there has been a lack of research comparing these two regimens for intermediate HC...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Moxuan Wang, Jiamin Cheng, Niansong Qian
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2024-10-01
coleção:	Scientific Reports
Assuntos:	Intermediate-stage hepatocellular carcinoma Lenvatinib Sorafenib Transcatheter arterial chemoembolization Portal hypertension Combination therapy
Acesso em linha:	https://doi.org/10.1038/s41598-024-74801-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!